World's largest producer of heparin API, made from pig-intestine mucosa, sold to global drugmakers.
World's largest producer of heparin API, made from pig-intestine mucosa, sold to global drugmakers.
Sells heparin API mainly to drugmakers who make blood thinners, and also its own finished enoxaparin injections, which pay more per unit. These H shares are the Hong Kong listing of the company also quoted as 002399.SZ.
In one line: A Chinese heparin-API dominant supplier.
Moat: narrow (scale, regulatory licence, distribution). Controls raw-material (pig mucosa) supply chain and FDA-audited API plants at global scale.
Headquarters: Shenzhen, China · Founded: 1998 · Employees: 2,150
Size Shenzhen Hepalink Pharmaceutical (9989.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.78B, the 435th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$3.98 on 18 Nov 2026.
Performance Over six months the shares fell 12.5%, against -0.8% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue fell 1.3% over the last twelve months (peer median +5.9%); the operating margin is 7.8% (peer median 10.0%).
Valuation It trades at 8.7× forward earnings against a peer median of 19.1× (cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -0 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.7 points below its cost of capital (7.8% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$5.76B | HK$5.92B | HK$5.72B | HK$6.02B | HK$8.32B |
| Revenue growth | — | +3% | -5% | -28% | — |
| Gross profit | HK$2.20B | HK$1.76B | HK$1.80B | HK$1.88B | HK$2.60B |
| EBITDA | n/a | HK$961M | HK$1.14B | HK$138M | HK$1.52B |
| Net income | HK$227M | HK$379M | HK$701M | -HK$865M | HK$846M |
| Free cash flow | HK$2.27B | HK$1.75B | HK$2.48B | HK$29.3M | -HK$981M |
| Capital expenditure | HK$121M | HK$131M | HK$220M | HK$492M | HK$259M |
| Total debt | HK$3.63B | HK$3.31B | HK$3.77B | HK$6.12B | HK$7.26B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shenzhen Hepalink Pharmaceutical 9989.HK | $1.78B | -13% | -1% | 8% | 8.7× | -0.4% |
| Yantai Dongcheng Biochemicals 002675.SZ | $1.59B | 0% | -4% | 15% | 47.2× | 6.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 9989.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.5% | -0.6% | 10th highest of 21 |
| 6-month return | -12.5% | -0.8% | 9th lowest of 21 |
| Distance from 52-week high | -31.0% | -33.8% | 10th highest of 21 |
| Revenue growth (TTM) | -1.3% | +5.9% | 6th lowest of 21 |
| Operating margin | 7.8% | 10.0% | 11th highest of 21 |
| Forward P/E | 8.7× | 19.1× | cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -0.4% | 5.4% | 6th least demanding of 16 |
| Growth delivered (Del g) | -0.2% | +8.2% | 2nd lowest of 16 |
| Hurdle (Req g minus delivered) | -0.2 pp | -6.6 pp | 7th most demanding of 16 |
| ROIC minus cost of capital | -2.7 pp | +1.2 pp | 10th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.78B | -13% | -1% | 8% | 8.7× | -0.4% | -0.2% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |